MYMD PHARMACEUTICALS INC (MYMD) Stock Price & Overview
NASDAQ:MYMD • US62856X2018
Current stock price
The current stock price of MYMD is 1.82 USD. Today MYMD is down by 0%. In the past month the price decreased by -2.15%. In the past year, price decreased by -94.48%.
MYMD Key Statistics
- Market Cap
- 4.204M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.18
- Dividend Yield
- N/A
MYMD Stock Performance
MYMD Stock Chart
MYMD Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to MYMD. When comparing the yearly performance of all stocks, MYMD is a bad performer in the overall market: 97.64% of all stocks are doing better.
MYMD Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to MYMD. MYMD scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
MYMD Earnings
MYMD Forecast & Estimates
MYMD Groups
Sector & Classification
MYMD Financial Highlights
Over the last trailing twelve months MYMD reported a non-GAAP Earnings per Share(EPS) of -0.18. The EPS increased by 52.63% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -32.43% | ||
| ROE | -43.95% | ||
| Debt/Equity | 0 |
MYMD Ownership
MYMD Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 25.94 | 855.344B | ||
| JNJ | JOHNSON & JOHNSON | 20.21 | 566.915B | ||
| MRK | MERCK & CO. INC. | 22.06 | 282.297B | ||
| PFE | PFIZER INC | 9.03 | 153.415B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.08 | 117.056B | ||
| ZTS | ZOETIS INC | 16.34 | 48.828B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.78 | 26.166B | ||
| VTRS | VIATRIS INC | 5.26 | 15.198B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.8 | 11.922B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.026B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.799B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 5.144B | ||
| LGND | LIGAND PHARMACEUTICALS | 24.12 | 4.084B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About MYMD
Company Profile
MyMD Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company, which engages in the development of drug products targeting aging, age-related, and autoimmune diseases, chronic pain, anxiety, and sleep disorders. The company is headquartered in Baltimore, Maryland and currently employs 9 full-time employees. The company went IPO on 2008-07-24. The firm is focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms. The Company’s MYMD-1 is a drug platform based on a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. The company also shows potential as an anti-fibrotic and anti-prolific therapeutic. The Company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. Supera-CBD is a synthetic, preclinical cannabidiol derivative that has been demonstrated to effectively target cannabinoid type 2 (CB2) receptors. Supera-CBD binds to and inhibits opioid receptors, comparing it side by side with plant-based cannabidiol (CBD).
Company Info
IPO: 2008-07-24
MYMD PHARMACEUTICALS INC
855 N. Wolfe Street, Suite 601
Baltimore MARYLAND 08086 US
CEO: Christopher C. Schreiber
Employees: 9
Phone: 18568488698
MYMD PHARMACEUTICALS INC / MYMD FAQ
What does MYMD PHARMACEUTICALS INC do?
MyMD Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company, which engages in the development of drug products targeting aging, age-related, and autoimmune diseases, chronic pain, anxiety, and sleep disorders. The company is headquartered in Baltimore, Maryland and currently employs 9 full-time employees. The company went IPO on 2008-07-24. The firm is focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms. The Company’s MYMD-1 is a drug platform based on a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. The company also shows potential as an anti-fibrotic and anti-prolific therapeutic. The Company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. Supera-CBD is a synthetic, preclinical cannabidiol derivative that has been demonstrated to effectively target cannabinoid type 2 (CB2) receptors. Supera-CBD binds to and inhibits opioid receptors, comparing it side by side with plant-based cannabidiol (CBD).
What is the current price of MYMD stock?
The current stock price of MYMD is 1.82 USD.
Does MYMD PHARMACEUTICALS INC pay dividends?
MYMD does not pay a dividend.
How is the ChartMill rating for MYMD PHARMACEUTICALS INC?
MYMD has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the market cap for MYMD PHARMACEUTICALS INC?
MYMD PHARMACEUTICALS INC (MYMD) has a market capitalization of 4.20M USD. This makes MYMD a Nano Cap stock.